English home · News 2026 · Deutsch
September 2026 topic. Published retrospectively on 13 November 2026. Law as at 13 November 2026. The article date provides a thematic position in the annual archive.
Breeding plans should connect health prognosis, association standards and contractual statements. Successful sales or association approval do not settle welfare compliance.
Make health predictions specific
Section 11b TierSchG addresses certain expected hereditary breeding effects. Assessment needs scientifically understandable analysis of animals and traits. General breed descriptions and isolated findings require careful interpretation. New knowledge may require reviewing matings and buyer information.
Align evidence and promises
Health tests each have a defined scope. Testing one risk is not a comprehensive future-health guarantee. Contracts and advertising should describe provable conditions precisely. Complaints require bringing together pedigree, findings, planning and actual buyer information.
Respond factually to authority allegations
Assess a hearing against its actual reasons. Expert counterarguments, further evidence or planning changes may matter. Lawfulness and remedies depend on content, stage and urgency. Parallel buyer claims require their own contractual basis.
Four practical examples
These examples illustrate typical situations. They do not report actual client matters.
Test covers only one trait
Advertising must not automatically imply complete hereditary health. Scope and wording must align.
New findings in offspring
Review affected lines and future plans traceably. Distinguish isolated observations from reliable prognosis.
Association permits mating
Approval does not replace independent assessment of the statutory prohibition.
Buyer demands return
Assess promises, health and remedies independently. A regulatory allegation alone does not decide a sale dispute.
Legal basis and further information
Official legislation / authority guidance · Detailed information on this practice area